Scpharmaceuticals Inc Revenue Growth Rates (SCPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Scpharmaceuticals Inc   (NASDAQ: SCPH)
 

SCPH's Revenue Growth by Quarter and Year

Scpharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCPH Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 16.04
1st Quarter March 11.75
FY 27.79





SCPH Revenue second quarter 2025 Y/Y Growth Comment
Scpharmaceuticals Inc reported Revenue surge of 99.27% year on year in the second quarter 2025, to $ 16.04 millions, this is lower than Scpharmaceuticals Inc 's recent average Revenue surge of 173.78%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue growth. While Scpharmaceuticals Inc ' s Revenue jump of 99.27% ranks overall at the positon no. 176 in the second quarter 2025.


SCPH Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 99.18 % - -
3rd Quarter September - 163.95 % - -
2nd Quarter June 99.27 % 390.85 % - -
1st Quarter March 92.62 % 196.12 % - -
FY   - 167.13 % - -

Financial Statements
Scpharmaceuticals Inc 's second quarter 2025 Revenue $ 16.04 millions SCPH's Income Statement
Scpharmaceuticals Inc 's second quarter 2024 Revenue $ 8.05 millions Quarterly SCPH's Income Statement


SCPH Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 21.14 % 60.53 % -
3rd Quarter September - 24.6 % 131.71 % -
2nd Quarter June 36.52 % 31.97 % -20.39 % -
1st Quarter March -3.29 % 0 % - -
FY (Year on Year)   - 167.13 % - -


Back to SCPH Growth rate Comparisons >> Back to SCPH Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #66
Overall #176

Revenue Y/Y Growth Statistics
High Average Low
391.7 % 173.78 % 92.59 %
(Dec 31 2024)   (Jun 30 2025)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #66
Overall #176
Revenue Y/Y Growth Statistics
High Average Low
391.7 % 173.78 % 92.59 %
(Dec 31 2024)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Scpharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
131.75 % 31.41 % -20.6 %
(Sep 30 2023)  


SCPH's II. Quarter Q/Q Revenue Comment
Scpharmaceuticals Inc achieved in the II. Quarter 2025 above company average sequential Revenue jump of 36.52%, to $ 16.04 millions, from $11.75 millions in the first quarter.
SCPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Scpharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 133.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #34
Overall #133
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #34
Overall #133
Revenue Q/Q Growth Statistics
High Average Low
131.75 % 31.41 % -20.6 %
(Sep 30 2023)  


SCPH's II. Quarter Q/Q Revenue Comment
Scpharmaceuticals Inc achieved in the II. Quarter 2025 above company average sequential Revenue jump of 36.52%, to $ 16.04 millions, from $11.75 millions in the first quarter.
SCPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Scpharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 133.


Scpharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 49.97 $ 41.98 $ 36.33 $ 30.28 $ 24.05
Y / Y Revenue Growth (TTM) 107.79 % 138.1 % 167.28 % - -
Year on Year Revenue Growth Overall Ranking # 60 # 50 # 50 # 0 # 0
Seqeuential Revenue Change (TTM) 19.02 % 15.55 % 19.99 % 25.91 % 36.39 %
Seq. Revenue Growth (TTM) Overall Ranking # 319 # 354 # 330 # 388 # 403


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2025 period, Scpharmaceuticals Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of 36.39% year on year, if the fiscal year would end at Jun 30 2025.
A slow-down in the Scpharmaceuticals Inc 's Revenue growth from the 11.75% growth in Mar 31 2025.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 50 to 60.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 21
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
167.28 %
 137.72 %
107.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 81
S&P 500 # 319
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2025 period, Scpharmaceuticals Inc 's cumulative twelve months Revenue were $ 50 millions, company would post below average annual Revenue growth of 107.79% year on year, if the fiscal year would end at Jun 30 2025.
A slow-down in the Scpharmaceuticals Inc 's Revenue growth from the 11.75% growth in Mar 31 2025.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 50 to 60.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 21
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
167.28 %
137.72 %
107.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 81
S&P 500 # 319




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SCPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Arcutis Biotherapeutics Inc 164.13%$ 164.126 millions
Ataibeckley Inc 163.37%$ 163.370 millions
Nexalin Technology Inc 163.00%$ 162.996 millions
Opus Genetics Inc 159.17%$ 159.173 millions
Crinetics Pharmaceuticals Inc 158.40%$ 158.396 millions
Serina Therapeutics Inc 154.90%$ 154.902 millions
Zymeworks Inc 153.21%$ 153.214 millions
Tarsus Pharmaceuticals Inc 151.54%$ 151.538 millions
Dyadic International Inc 150.49%$ 150.490 millions
Sutro Biopharma Inc 147.98%$ 147.977 millions
Verrica Pharmaceuticals Inc 145.35%$ 145.354 millions
Liquidia Corporation141.51%$ 141.514 millions
Neuronetics Inc 133.38%$ 133.377 millions
Abcellera Biologics Inc 133.29%$ 133.292 millions
Catheter Precision Inc 127.96%$ 127.957 millions
Eton Pharmaceuticals Inc 119.38%$ 119.383 millions
Elite Pharmaceuticals Inc 112.32%$ 112.322 millions
Travere Therapeutics Inc 111.49%$ 111.488 millions
Ac Immune Sa108.30%$ 108.296 millions
Cellectis S a 107.48%$ 107.480 millions
Neuroone Medical Technologies Corp105.39%$ 105.389 millions
Intellia Therapeutics Inc 104.76%$ 104.758 millions
Anaptysbio Inc 102.93%$ 102.926 millions
Ionis Pharmaceuticals Inc 100.69%$ 100.688 millions
Scpharmaceuticals Inc 99.17%$ 99.168 millions
Stereotaxis Inc 98.91%$ 98.910 millions
Lineage Cell Therapeutics Inc 96.38%$ 96.378 millions
Carlsmed Inc 95.18%$ 95.182 millions
Iovance Biotherapeutics inc 92.73%$ 92.735 millions
Tg Therapeutics Inc 92.13%$ 92.127 millions


About Scpharmaceuticals Inc Revenue Growth Rates (SCPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Scpharmaceuticals Inc (CIK 1604950).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-25-175437
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Scpharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.